FUSION
3 jaar en 11 maanden per deelnemer
Medicijnstudies
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations. This study is sponsored by Ionis Pharmaceuticals.
